Research compound supplied in Australia by Pulse Biolabs for laboratory use. Available in 2mg.
The body’s own growth hormone-releasing hormone survives minutes in the blood. CJC-1295 was engineered to send the same signal for days, and the two versions sold under the name differ in exactly that.
CJC-1295 is a modified copy of the active segment of growth hormone-releasing hormone (GHRH), the brain signal that tells the pituitary to release growth hormone. This is the DAC form: a chemical group bonds it permanently to albumin in the blood so the signal lasts days rather than minutes. Two small phase 1 trials in healthy adults measured raised growth hormone and IGF-1; there are no outcome trials and no regulatory approval.
Read the full research note →| Presentation | Code | Status | Price |
|---|---|---|---|
| 2mg | CD2 | In stock | $75 |
No batch-specific test report is currently published for this product. What a report does and does not show.
Supplied as lyophilised (freeze-dried) powder in a sealed vial. Store sealed and protected from light at the conditions stated on the product label or supplied specification. Solvent choice, concentration and handling after reconstitution depend on the compound and on the laboratory’s own procedures, and are not specified here.
CJC-1295, with or without DAC, is not an approved medicine in Australia, and no approval elsewhere was identified. Growth hormone-releasing factors are prohibited at all times in sport under WADA category S2.
Status checked 2026-09-23. Details and sources in the research note.